By Peter Loftus
Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu.
Moderna and Novavax shares rose more than 10%, while CureVac increased 5%.
The companies are developing experimental vaccines against pandemic influenza, including the avian H5N1 strain that has infected more than 60 people in the U.S. in the past year, mostly from animal-to-human exposures.
Moderna's efforts are part of a $176 million federal contract it received last year.
The death in Louisiana could spur more federal funding for the vaccines' development, or purchase orders if the vaccines succeed in testing and are authorized by regulators. A vaccine could be given to at-risk people such as farm workers, hunters or bird hobbyists.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
January 07, 2025 13:40 ET (18:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。